REVIEW

REVISED Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism [version 2; peer review: 2 approved]

Marcos Palacio Rojas ^{1,2}, Carem Prieto¹, Valmore Bermúdez ^{1,3}, Carlos Garicano³, Trina Núñez Nava², María Sofía Martínez¹, Juan Salazar ¹, Edward Rojas⁴, Arturo Pérez⁴, Paulo Marca Vicuña², Natalia González Martínez², Santiago Maldonado Parra², Kyle Hoedebecke ^{5,6}, Rosanna D'Addosio ⁷, Clímaco Cano¹, Joselyn Rojas⁸

¹Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, Venezuela

²Hospital Básico de Paute, Public Health Ministry, Paute, Ecuador

³Grupo de Investigación Altos Estudios de Frontera (ALEF), Universidad Simón Bolívar, Cúcuta, Colombia

⁴Department of Medicine, Rutgers University, Newark, NJ, 07103, USA

⁵WONCA Polaris - USA, Bangkok, 10500, Thailand

⁶Yongsan Health Clinic, Seoul, 96205, South Korea

⁷Department of Public Health, School of Medicine, University of Zulia, Maracaibo, Venezuela

⁸Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA

V2 First published: 30 Nov 2017, 6:2073
<https://doi.org/10.12688/f1000research.12938.1>
 Latest published: 01 Oct 2018, 6:2073
<https://doi.org/10.12688/f1000research.12938.2>

Abstract

The direct link between lipid metabolism alterations and the increase of cardiovascular risk are well documented. Dyslipidemias, including isolated high LDL-c or mixed dyslipidemia, such as those seen in diabetes (hypertriglyceridemia, high LDL-c or low HDL-c), correlate with a significant risk of cardiovascular and cerebrovascular disease worldwide. This review analyzes the current knowledge concerning the genetic basis of lipid metabolism alterations, emphasizing lipoprotein lipase gene mutations and the HindIII polymorphism, which are associated with decreased levels of triglycerides and LDL-c, as well as higher levels of HDL-c. These patterns would be associated with decreased global morbidity and mortality, providing protection against cardiovascular and cerebrovascular diseases.

Keywords

Dyslipidemia, Polymorphisms, HindIII, Lipoprotein Lipase, coronary artery disease

Open Peer Review

Approval Status

	1	2
version 2 (revision) 01 Oct 2018		 view
version 1 30 Nov 2017	 view	 view

1. **David J. Galton**, The Royal London and St. Bartholomew's Hospitals, London, UK
2. **Carlos Aguilar-Salinas** , Unidad de Investigación de Enfermedades Metabólicas, México City, Mexico

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Marcos Palacio Rojas (marcos.palacio@gmail.com)

Author roles: **Palacio Rojas M:** Conceptualization, Data Curation, Investigation, Methodology, Project Administration, Supervision, Validation, Writing – Original Draft Preparation; **Prieto C:** Conceptualization, Data Curation, Formal Analysis, Writing – Original Draft Preparation; **Bermúdez V:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation; **Garicano C:** Conceptualization, Data Curation, Project Administration, Validation, Visualization; **Núñez Nava T:** Conceptualization, Data Curation, Investigation, Validation; **Martínez MS:** Conceptualization, Data Curation, Investigation; **Salazar J:** Conceptualization, Data Curation, Investigation; **Rojas E:** Conceptualization, Data Curation, Resources; **Pérez A:** Data Curation, Formal Analysis, Writing – Original Draft Preparation; **Marca Vicuña P:** Data Curation, Formal Analysis, Investigation, Methodology; **González Martínez N:** Data Curation, Resources, Software; **Maldonado Parra S:** Conceptualization, Validation, Visualization; **Hoedebecke K:** Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **D'Addosio R:** Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing; **Cano C:** Data Curation, Writing – Original Draft Preparation; **Rojas J:** Conceptualization, Supervision, Writing – Original Draft Preparation

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Technological, Humanistic, and Scientific Development Council (Consejo de Desarrollo Científico, Humanístico y Tecnológico; CONDES), University of Zulia (grant n° CC-0437-10-21-09-10).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Palacio Rojas M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Palacio Rojas M, Prieto C, Bermúdez V *et al.* **Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism [version 2; peer review: 2 approved]** F1000Research 2018, 6:2073 <https://doi.org/10.12688/f1000research.12938.2>

First published: 30 Nov 2017, 6:2073 <https://doi.org/10.12688/f1000research.12938.1>

REVISED Amendments from Version 1

We made several modifications based on the reviewer input. In the "Dyslipidemia: The Current Status" section the last four paragraphs were reworded and updated. This allows for improved reading comprehension and better supporting evidence. Per Reviewer 2 request, we added information about ABCA1 into our manuscript under the "Dyslipidemia Genetics" section. The written portion of the other genes was also reworded for improved comprehension and flow. In the "LPL Polymorphism" section we added more details about Ser447x and reworded both the PvuII and HinfI details. Finally, the "HindIII (rs320) Polymorphism" section received additional details in the first, penultimate, and last paragraphs. The authors feel this is a much stronger rendition of the manuscript that achieves the requested changes.

See referee reports

Dyslipidemia: The current status

The relationship between dyslipidemia and atherosclerosis continues to be an area of active research, since the prevalence of atherosclerosis and associated cardiovascular complications continue to increase in the industrialized world¹. Cardiovascular disease (CVD) constitutes the greatest cause of morbidity and mortality globally with a high incidence in countries of all economic categories². Evidence supporting a causal relationship between lipid profile abnormalities and the risk of coronary artery disease (CAD) is overwhelming, confirming that hypercholesterolemia is an independent risk factor for CVD³⁻⁵. In addition, hypertriglyceridemia and mixed dyslipidemias have been associated with the aggregation of metabolic risk factors, like hypertension (HTN)⁶ and obesity⁷.

Dyslipidemias are a group of metabolic derangements characterized by any or a combination of the following: elevated low density lipoprotein (LDL-c) (>130mg/dL), elevated total cholesterol (>200 mg/dL), elevated TG (>150mg/dL), or low high density lipoprotein (HDL-c) (<40mg/dL in men and <50mg/dL in women)⁸.

The worldwide prevalence of dyslipidemia varies between different individuals, depending on race, age, socio-economic and cultural factors, lifestyle and genetics. This prevalence has increased significantly in growing cities with economic growth⁹. The factors are undoubtedly related to high calorie intake described by other Western nations¹⁰; while lower prevalence has been reported for these pathologies in Canada and South Korea where 45% and 44.1% of their respective populations present evidence of dyslipidemia^{11,12}. The difference of prevalence in these nations is indisputably tied to lifestyle with various publications highlighting diets rich in fiber and low in fats and refined sugars^{13,14}.

In Brazil, de Souza *et al.* 2003¹⁵ reported the most frequent dyslipidemias in their 1039 sample population were isolated low HDL-C (18.3%), hypertriglyceridemia (17.1%), and isolated hypercholesterolemia (4.2%). These results differ from those reported in the CARMELA study from Mexico between 2003 and 2005¹⁶, where the incidence of dyslipidemia in 1722 person sample size reported 16.4% with hypercholesterolemia and

32.5% with hypertriglyceridemia - slightly higher than those reported in Brazil. The differences could be related to the food preferences within Mexico, which include greater amounts of fat, simple sugars, and processed ingredients¹⁷. It must also be noted that these studies are over 10 years old as no more recent publications in Latin America were found. With the continued rise in dyslipidemias and obesity, these numbers do not necessarily reflect the current reality of these pathologies in the studied populations.

In Venezuela, the CARMELA study evaluated the prevalence of these lipid metabolism disorders in the city of Barquisimeto. The researchers found 59.6% of the 1824 subjects to suffer from dyslipidemia in 2003¹⁸. A decade later, Linares *et al.*¹⁹ published a study of 1892 sample size from the city of Maracaibo, Venezuela showing a prevalence of 84.8% - the highest figure reported to date. The difference of prevalence is related to both the ten year gap between the studies as well as the regional differences between the sample populations. Even though these two studies occurred in Venezuela, the two sites have different cultures, climate, and completely different nutritional food preferences. The diet of the latter is traditionally high in calories, protein, and carbohydrates with an elevated alcohol intake²⁰ while only 40% of the former ever ate fast food or other foods outside the home²¹.

In the majority of the studies of prevalences there is a clear tendency to evaluate younger populations, (22–24 years of age) as in the study by Barja *et al.* between 2009–2011²³ where 2900 school-age children were evaluated with the average age of 11.42±0.97 years old. Of this sample, 9.4% had isolated hypertriglyceridemia, 7.6% with low HDL-C, 4.9% with isolated hypercholesterolemia, 6.24% with atherogenic dyslipidemia, and 3.9% with mixed dyslipidemia. The existence of hyperlipidemia increases the potential for deposits on the tunica intima and the formation of arterial plaques. A correct early diagnosis of dyslipidemia allows for timely preventive intervention resulting in a reduction cardiovascular disease and facilitates the patient's clinical treatment²⁵.

Dyslipidemia genetics

The association between family history of dyslipidemia and the risk of CVD is supported by a large body of evidence¹⁸⁻²². Additionally, the great advancement in DNA analysis techniques has aided research surrounding CVD and related genetics and epigenetics. Understanding gene mutations or polymorphisms involved in the synthesis, transport, and metabolism of lipoproteins allows recognition of potential therapeutic targets and alternative treatments through identification of new molecules^{1,3,20}.

Dyslipidemia is one of the most well characterized cardiovascular risk factors^{19,20}. This not only depends on diet, but also on the synthesis and metabolism of lipoproteins conditioned by gene expression. Given the importance and the great diversity of proteins that participate in lipid metabolism, one might expect that a single defect in any step of gene expression would affect the quantity or quality of the product and potentially predispose to dyslipidemias and CVD¹⁹.

One genetic abnormalities associated with low HDL-c and increased CVD risk is the *Taq IB* polymorphism located in chromosome 16q21. This gene alters cholesteryl ester protein transferase (CEPT), which decreases HDL-c concentration²³. Some deletions, inversions, and substitutions of the *APO AI-IV*, *CII*, and *CIII* genes are also associated with both premature CVD and low HDL-c^{24,25}. Total deficiency of lecithin cholesterol acyl transferase (LCAT) can be seen after transition of C→T in codon 147 of exon 4 (W147R), G→A in codon 293 of exon 6 (M293I), as well as partial deficiencies of LCAT due to transition of C→T. Additionally, the substitution of threonine for isoleucine in codon 123 (T123I) causes decreased HDL-c and higher cholesterol in the intima of arterial vessels^{26,27}.

Below, some of the genetic alterations associated with low levels of HDL-c and a higher risk of CVD are highlighted:

- *CETP*: This mediates the exchange of lipids between lipoproteins. With high levels of *CETP*, HDL are transitioned into triglycerides (TGs), becoming the substrate for hepatic lipase where TGs are hydrolyzed. Apoprotein A (Apo) A-1 is degraded in tubular renal cells and diminishes the amount of HDL-C - increasing the atherogenic potential. The polymorphism rs1801706 (c.*84G>A) of the *CETP* gene is associated with CAD²⁷.
- *Familial hypoalphalipoproteinemia and HDL-C deficiency*: Approximately 50% of the HDL-C alterations are explained by polygenic defects in various chromosomal loci that control apolipoprotein expression (A-I, A-II, C-II, C-III y A-IV). Multiple genetic variations such as deletions, inversions, and substitutions of gene coding for apolipoproteins are associated with severe CAD^{28,29}.
- *LCAT*: This liver-synthesized enzyme circulates in plasma forming complexes with HDL and participating in the inverse transport of cholesterol. LCAT deficiencies cause an accumulation of free cholesterol in tissues. One of the most recent described gene alterations is the P-274-S polymorphism that affects biogenesis of HDL-C³⁰ and favors development of CVD.
- *ABCA1*: This protein mediates the transport of cholesterol and phospholipids from the cells to LDL. The C-69-T polymorphism of the gene codifies this protein and alterations can result in lower levels of HDL-C with higher levels of TG in obese children³¹. Additionally, the rs2515602, rs2275542, rs1800976, and rs4149313 polymorphisms are associated with obesity and can negatively affect one's lipid profile base on one study performed on 535 Chinese patients³².
- *FTO*: This includes a group of 45 genes related to obesity that were grouped together during phylogenetic analysis³³ and perform an important function in the regulation of food ingestion. *FTO* mutations are associated with obesity, metabolic syndrome and CAD³⁴. The literature does not specify which lipid metabolism genes affect *FTO*, but the rs9939609 polymorphism is associated with low HDL-C levels.

The following are some genetic alterations associated with hypercholesterolemia and hypertriglyceridemia, including their relationship with increased cardiovascular risk:

- *LDLR* gene - LDL-C receptor and familial hypercholesterolemia (FH): LDL-C is a macromolecular complex that transports cholesterol and cholesteryl esters from the liver to other peripheral tissues, where cholesterol is introduced to the cells through LDL receptors (LDLR)³⁶. FH, an autosomal dominant condition caused by mutations on the *LDLR* gene, is one of the best characterized genetic defects^{37,38}. Mutations on this lipoprotein or one of the proteins involved in its metabolism induce hypercholesterolemia and elevated LDL-C - both factors predisposing to the premature CAD development.
- *APO B-100* gene – ligand of LDL-C receptor and Familial Apolipoprotein B dysfunction (hypercholesterolemia type B). *ApoB-100* is the principle apolipoprotein in LDL and the ligand of LDLR. The autosomal dominant dyslipidemia known as Familial *APO B-100* Dysfunction (FDB) and is due to mutations in *ApoB-100*³⁹. Recently two new mutations on this gene have been described - p.Arg1164Thr and p.Gln4494. These variants have problems with binding to LDLR⁴⁰ where carriers of this mutation bear a greater cardiovascular risk.
- *APO E* gene – Apolipoprotein E and hyperlipoproteinemia or hyperlipidemia type III. Apolipoprotein E (ApoE) is a principal component of chylomicrons (CMs), very low density lipoprotein (VLDL) and some HDL-C. Its main function is to serve as the ligand for hepatic receptors for the remnants of the aforementioned lipoproteins and regulation of VLDL production. Alterations in this apoprotein cause hyperlipoproteinemia or Type III Hyperlipidemia (HLP III) where the plasma levels of cholesterol and triglycerides are increased²⁶. The polymorphisms in ApoE are associated with variations in plasma cholesterol levels where individuals with this allele mutation exhibit cholesterol levels 10% greater than average⁴¹.
- *Lp(a)* Gene: This is formed by a nucleus rich in cholesterol esters, phospholipids, and an ApoB-100 that contains a union site for LDL receptors, but still contains an ApoA molecule. Lp(a) consists of one of the most important cardiovascular risk factors and proves of greater significance when correlated with elevated levels of LDL-C - observed commonly in patients under 60 years old with CVA⁴². Polymorphisms have been found consisting of variable repetitions of module 4 where the number of repetitions is inversely proportional to the plasma levels of Lp(a)⁴³. Recent work has encountered differences in the distribution of the diverse alleles of ApoA among patients with atherosclerosis and

the isoforms of low weight molecular B, S1, and S2. These are found most frequently in carriers of coronary insufficiency who also show elevated levels of Lp(a)⁴⁴. This suggests that the short alleles of ApoA contribute to atherogenesis, increasing the plasma concentration of Lp(a).

- HL gene - hepatic lipase and phenotype of combined familial hyperlipidemia. Combined familial hyperlipidemia is a genetic lipid disorder that accounts for 10–20% of premature CAD worldwide. Affected individuals exhibit hypercholesterolemia and/or hypertriglyceridemia and elevated concentrations of APO B, with low values of HDL-c. These are collectively called iatrogenic lipoproteinemia phenotype. There have been demonstrations of alterations in common genetic loci between families of both combined familial hyperlipidemia phenotype and atherogenic lipoproteinemia phenotype. (ALP). Such loci include genes of superoxide manganese dismutase, transport proteins of cholesteryl esters/lecithin, cholesterol acyl transferase and AI-CIII-AIV, as well as a great variety of studies relating polymorphisms in the promoter region of the LH gene (C-480T and C-514T polymorphisms) with lowering on plasma levels of HDL-C^{45,46}.
- *ApoCIII: Apoprotein CIII*: This Apo inhibits the activity of LPL. It is a component of the lipoprotein remnants that possess elevated TG levels. The loss of function of this Apo has been associated with low TG levels and a reduction of coronary artery calcification⁴⁷. The polymorphism C3175>G localized in region 3' presents in less than 5% of the population in the UK. Those who present with this polymorphism have elevated TGs and deficient LPL - augmenting the probability of developing CVA. Currently the pharmaceutical companies Isis and Ionis have developed an antisense oligonucleotide that blocks ARNm for ApoCIII. This is currently in phase 2 of clinical trials and preliminary studies show a significant decline of TGs in patients with ApoCIII mutations⁴⁸.
- LPL gene - lipoprotein lipase, Apo CII and familial dyslipidemia type O or familial chylomicronemia. Any mutations on the LPL gene, which results in a partial deficiency of the enzyme, will cause an increase in TG concentration. This is the basis of familial chylomicronemia, familial dyslipidemia type I or familial hypertriglyceridemia; These are monogenic diseases with autosomal recessive inheritance, consisting with pure hypertriglyceridemia, TG values of 300 to 800 mg/dl, cholesterol <240 mg/dl, increases in VLDL and CMs, and lowering of LDL-C and HDL-C. To date, some LPL variants have been characterized because of amino acids substitutions in different positions (D9N, N291S, substitutions of glycine for glutamine on codon 188 and serine for a termination signal on codon 4)⁴⁷. The enzymatic activity of LPL is also lowered by mutations of

the ApoCII gene, an essential activator of LPL. Specifically, the mutation R72T of the ApoCII gene causes severe hypertriglyceridemia and recurrent pancreatitis⁴⁹.

This information justifies the use of genetic markers for early diagnosis and cardiovascular risk assessment, especially in children and adolescents, in order to adopt early nutritional or pharmacologic interventions with the aim to mitigate atherosclerotic artery disease.

Lipoprotein lipase

The *LPL* gene is located on the short arm of chromosome 8, on the region 21.3 (8p21.3). It is formed of 10 exons and 9 introns (Figure 1), and the gene codifies a protein of 475 amino acids^{53,54}.

LPL is a multifunctional glycoprotein enzyme that plays an important role on lipid metabolism. After being secreted, it adheres to the luminal surface of endothelial cells where it hydrolyzes TG in circulating lipoproteins. This constitutes the limiting step on lipoprotein elimination, such as CMs from exogenous sources, and those endogenous sources, like VLDL, in circulation^{55,56}.

In this way, *LPL* affects serum levels of TG, generating lipoprotein remnants that are processed by hepatic lipase. Recently, it has been demonstrated that *LPL* serves as a ligand for the protein related to the LDLR and influences hepatic secretion and VLDL and LDL-c capture⁵⁷. Additionally, *LPL* has been linked to the retention of LDL-c by the sub-endothelial matrix and arterial wall, increasing LDL and VLDL conversion into more atherogenic forms⁵⁸. Genetic modifications can affect *LPL* activity, which results in changes in lipid metabolism. Examples are slow hydrolysis of CMs and VLDL-c, longer LDL-c half-life, and decreased production of HDL^{59,60}.

Around 100 mutations have been described on the *LPL* gene. The most frequent are Asp9sn, Gly188Glu and Asn291Ser. The mutations in the homozygous form are associated with hyperlipoproteinemia type I (familial chylomicronemia). Heterozygous mutations have a significant incidence in the general population (3–7%) and leads to up to a 50% decreased activity of *LPL*, causing an increase in TG and a decrease in HDL-c. All these lipid profile patterns increase the risk of CVD⁶¹.

LPL gene polymorphisms

Genetic studies have revealed around 100 mutations and polymorphisms in simple nucleotides on the *LPL* gene, some are protective, which others are deleterious:

1. *Ser447x (rs328) polymorphism* is located in exon 9, where cytosine is substituted by guanine on position 1959. This polymorphism leads to the suppression of both final amino acids, serine and glycine on position 447 of the protein that codifies a *LPL* protein prematurely truncated, which has increased lipolytic activity and increased levels of post-heparin LPL activity in X447

Figure 1. Chromosomal origin of the LPL gene. The authors confirm that this is an original image and has not been re-used or adapted from another source.

carriers. This is associated with the variant Ser447X, with low levels of TG, small increases of HDL-C levels, and a moderate CVD risk reduction⁶². These results differ from those of Emamian *et al.*⁶¹ who studied 271 obese individuals and reported elevated TGs in carriers of this polymorphism. In studies of postprandial lipids, it has been reported that the aforementioned carriers present with elevated blood glucose and TGs than non-carriers⁶². These reports clearly indicate that the benefit of this mutation are limited in patients of normal weight under the evaluated conditions.

2. *PvuII* (*rs285*) polymorphism, located on intron 6, is located 1.57 kb from the Splicing Acceptor (SA) site. This polymorphism is the product of a change of cytosine for thymine. The region containing the *PvuII* site is similar to the splice location. This suggests that a change at C497-T may interfere with the correct splicing of mRNA. Even though the physiological role associated with this polymorphism is not completely clear, it has been associated with high TG and low HDL-C levels⁶³. A meta analysis revealed that this polymorphism reduces the risk of suffering from an MI⁶⁴ and, therefore, appears to have a protective effect against CVA.
3. *HindIII* (*rs320*) polymorphism is one of the most common polymorphisms of *LPL* gene (see below).

***HindIII* (*rs320*) polymorphism**

HindIII is a transition of intronic bases of thymine (T) to guanine (G) on position 495 of intron 8 of the *LPL* gene, which eliminates the restriction site for the *HindIII* enzyme (Figure 2 and Figure 3). Sequential analysis has determined that this HINDIII recognition site corresponds with the binding consensus sequence for the transcription factors Sp1, GATA, C/EBP, and TBP. The first three are implicated in the regulation of the gene transcription involved in lipid metabolism^{65–67}. The transcription factor TBP (the binding protein for the TATA box) initiates the formation of the preinitiation complex that permits gene transcription for part of RNA polymerase II⁶⁸. Mobility shift electrophoresis has shown that human vascular smooth muscle cells and COS-1 cell carriers of the G/G allele demonstrated reduced TBP binding affinity⁶⁹. This indicates less LPL expression in polymorphism carriers, conferring functionality of said SNP.

HindIII is one the most frequent polymorphisms found in various studies, which show that the homozygous genotype T/T (H⁺/H⁺) represents from 45.1 to 56.4% of Iranian and south Indian populations, respectively most frequent, followed by the heterozygous T/G with 35.8–36.6% and homozygous G/G (H⁻/H⁻), with 6.93–19%^{64,65}. Similar results have been reported in Europe^{66,67} and Brazil⁶⁸.

The allele H⁺ (presence of thymine “T” or restriction site of *HindIII* enzyme) results in a cut on the base pair sequence in two bands of 217pb and 139pb. This is associated with a decrease in the activity of *LPL* in comparison with the allele H⁻ (presence of “G” or absence of the enzymatic restriction site or presence of *HindIII* polymorphism). With 137pb, in which there is no cut in the *LPL* gene intron 8 sequence, maintaining a unique sequence of 356pb (Figure 4)⁶⁹, leading to both alterations in lipidic metabolism and cardiovascular risk profile modifications in these populations.

Some studies have demonstrated that the common allele (T or H⁺) is associated with lower levels of HDL-c in contrast with the uncommon allele (G or H⁻)^{70,71}. In addition, those individuals with H⁺/H⁺ genotype had a higher concentration of serum levels of TG when compared with homozygous genotype H⁻/H⁻^{66,67,70,72}. Similarly, there have been reports of high serum levels of LDL-c⁷¹ and a higher global cardiovascular risk in patients who carry the common allele (T or H⁺), see Table 1. Some studies had reported a significant drop in the *LPL* activity among carriers of the uncommon G allele when compared with the more common allele T⁵⁷.

LPL expressed by macrophages and other cells contained in the vascular walls is involved in the early atherogenic process and is associated with increased atherosclerosis. Overexpression of *LPL* is also associated with insulin resistance and HTN by increased sodium retention, inflammation, vascular remodeling, sympathetic nervous system activation, oxidative stress and vasoconstriction^{73–75}.

On the other hand, HTN (mostly systolic) has been shown to be associated with the polymorphism *HindIII* in the Mexican population in studies by Muñoz-Barrios *et al.*⁷⁶. Similarly, the homozygous genotype for the common allele (H⁺) was associated with a higher risk of myocardial infarction in

Ahmadi *et al.*⁸⁷ also showed no significant association between the gene and CAD in the 115 Swiss subjects evaluated. These findings are in contrary to the expected improved cardio-cerebral function expected and leave this line of research open for future investigations.

This polymorphism has not only been associated with HA, rather also with insulin resistance. This is best demonstrated with a study of 110 Asian females with gestational diabetes who were found to have a reduced resistance to insulin than carriers of this rare allele⁸⁸.

From a neurologic point of view, there is scant data associating homozygous common genotype (H+/H+) with the development of Alzheimer's disease of late appearance. This is founded on the *LPL* function in regulation cognitive function, mediated by cholesterol and Vitamin E transport to neuronal cells on the hippocampus and other brain areas⁶⁴.

These investigations suggest that the presence of the HindIII polymorphism exerts a positive influence in lipid metabolism in patients with normal BMI. Future studies should focus in more detail on the protective function of this genetic factor in the general population.

Conclusions

Dyslipidemias are independent risk factors for atherosclerotic artery disease. High TC, TAG and LDL-C, as well as decreased serum HDL-C, are frequently associated with low physical activity and poor eating habits, but there is a large number of mutations and single nucleotide polymorphism related to a specific protein dysfunction within major lipoprotein metabolism pathways like CETP, ApoA, LCAT, LDL receptor, Apo B-100 and LPL.

In this regard, the *LPL* gene *HindIII* polymorphism (rare allele H-) poses a protective function through its role in producing an improved lipid profile (low TG and LDL-c and high HDL-c). On the other hand, the presence of common allele (T or H+) is associated with pro-atherogenic dyslipidemias and raised cardiovascular risk. The uncommon allele (G or H-) with an absence of restriction *HindIII* enzyme exhibits a lower prevalence of at least 20% according to the current available literature.

There are no studies in Venezuela that allows us to know the true prevalence of the HindIII polymorphism, nor to corroborate the association with changes in the lipid profile or an increased risk for cardiovascular diseases, so we suggest performing a national populational genetic study in search for this lipidic disorders with the aim to has a better understanding of the cardiovascular risk factors in Latin America.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Grant information

This work was supported by the Technological, Humanistic, and Scientific Development Council (Consejo de Desarrollo Científico, Humanístico y Tecnológico; CONDES), University of Zulia (grant n° CC-0437-10-21-09-10).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Helkin A, Stein JJ, Lin S, *et al.*: **Dyslipidemia Part 1--Review of Lipid Metabolism and Vascular Cell Physiology.** *Vasc Endovascular Surg.* 2016; **50**(2): 107–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Murray CJ, Lopez AD: **Mortality by cause for eight regions of the world: Global Burden of Disease Study.** *Lancet.* 1997; **349**(9061): 1269–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gordon DJ, Probstfield JL, Garrison RJ, *et al.*: **High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.** *Circulation.* 1989; **79**(1): 8–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Isomaa B, Almgren P, Tuomi T, *et al.*: **Cardiovascular morbidity and mortality associated with the metabolic syndrome.** *Diabetes Care.* 2001; **24**(4): 683–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Carr MC, Brunzell JD: **Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.** *J Clin Endocrinol Metab.* 2004; **89**(6): 2601–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Onat A, Hergenç G, Sari I, *et al.*: **Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study.** *Am J Hypertens.* 2005; **18**(3): 409–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brown CD, Higgins M, Donato KA, *et al.*: **Body mass index and the prevalence of hypertension and dyslipidemia.** *Obes Res.* 2000; **8**(9): 605–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Joffres M, Shields M, Tremblay MS, *et al.*: **Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey.** *Can J Public Health.* 2013; **104**(3): e252–257.
[PubMed Abstract](#) | [Publisher Full Text](#)
- İlhan Ç, Beytullah Y, Şemsettin Ş, *et al.*: **Serum lipid and lipoprotein levels, dyslipidemia prevalence, and the factors that influence these parameters in a Turkish population living in the province of Tokat.** *Turk J Med Sci.* 2010; **40**(5): 771–82.
[Publisher Full Text](#)
- Tóth PP, Potter D, Ming EE: **Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006.** *J Clin Lipidol.* 2012; **6**(4): 325–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lee MH, Kim HC, Ahn SV, *et al.*: **Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998–2005.** *Diabetes Metab J.* 2012; **36**(1): 43–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- de Souza LJ, Souto Filho JT, de Souza TF, *et al.*: **Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian state of Rio de Janeiro.** *Arq Bras Cardiol.* 2003; **81**(3): 249–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, *et al.*: **Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006.** *Salud Publica Mex.* 2010; **52** Suppl 1: S44–53.
[PubMed Abstract](#) | [Publisher Full Text](#)

14. Chiqui RA, Bermúdez V, Añez R, *et al.*: **Prevalencia de dislipidemia y factores asociados en la ciudad de Cuenca, Ecuador.** *Síndrome Cardiometaabólico*. 2014; 4(2): 31–41.
[Reference Source](#)
15. Vinueza R, Boissonnet CP, Acevedo M, *et al.*: **Dyslipidemia in seven Latin American cities: CARMELA study.** *Prev Med*. 2010; 50(3): 106–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Linares S, Bermúdez V, Rojas J, *et al.*: **Prevalencia de dislipidemias y factores psicobiológicos asociados en individuos adultos del municipio Maracaibo, Venezuela.** *Síndrome Cardiometaabólico*. [Internet]. 2015; 3(3): 63–75.
[Reference Source](#)
17. Bermúdez V, Salazar J, Rojas J, *et al.*: **Prevalence, Lipid Abnormalities Combinations and Risk Factors Associated with Low HDL-C Levels in Maracaibo City, Venezuela.** *J J Commun Med*. 2015; 1(2): 9.
[Reference Source](#)
18. Miller M: **Dyslipidemia and cardiovascular risk: the importance of early prevention.** *QJM*. 2009; 102(9): 657–667.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Lusis AJ, Rotter JI, Sparkes RS, *et al.*: **Molecular Genetics of Coronary Artery Disease: Candidate Genes and Processes in Atherosclerosis.** *Monogr Hum Genet*. Karger, 1992; 14: I–XVII.
[Publisher Full Text](#)
20. Genest JJ Jr, Martin-Munley SS, McNamara JR, *et al.*: **Familial lipoprotein disorders in patients with premature coronary artery disease.** *Circulation*. 1992; 85(6): 2025–2033.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Aulchenko YS, Ripatti S, Lindqvist I, *et al.*: **Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.** *Nat Genet*. 2009; 41(1): 47–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Nordestgaard BG, Chapman MJ, Humphries SE, *et al.*: **Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.** *Eur Heart J*. 2013; 34(45): 3478–90a.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Boekholdt SM, Sacks FM, Jukema JW, *et al.*: **Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.** *Circulation*. 2005; 111(3): 278–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Ikewaki K, Matsunaga A, Han H, *et al.*: **A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease.** *Atherosclerosis*. 2004; 172(1): 39–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Paulweber B, Friedl W, Krempler F, *et al.*: **Genetic variation in the apolipoprotein AI-CIII-AIV gene cluster and coronary heart disease.** *Atherosclerosis*. 1988; 73(2–3): 125–133.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Holleboom AG, Daniil G, Fu X, *et al.*: **Lipid oxidation in carriers of lecithin: cholesterol acyltransferase gene mutations.** *Arterioscler Thromb Vasc Biol*. 2012; 32(12): 3066–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Funke H, von Eckardstein A, Pritchard PH, *et al.*: **Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.** *J Clin Invest*. 1993; 91(2): 677–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. de Grooth GJ, Klerkx AH, Stroes ES, *et al.*: **A review of CETP and its relation to atherosclerosis.** *J Lipid Res*. 2004; 45(11): 1967–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Saeedi R, Li M, Frohlich J: **A review on lecithin:cholesterol acyltransferase deficiency.** *Clin Biochem*. 2015; 48(7–8): 472–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Levinson SS, Wagner SG: **Implications of reverse cholesterol transport: recent studies.** *Clin Chim Acta*. 2015; 439(Supplement C): 154–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Brown MS, Goldstein JL: **A receptor-mediated pathway for cholesterol homeostasis.** *Science*. 1986; 232(4746): 34–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Hobbs HH, Brown MS, Goldstein JL: **Molecular genetics of the LDL receptor gene in familial hypercholesterolemia.** *Hum Mutat*. 1992; 1(6): 445–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Soria LF, Ludwig EH, Clarke HR, *et al.*: **Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.** *Proc Natl Acad Sci U S A*. 1989; 86(2): 587–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Fouchier SW, Defesche JC, Kastelein JJ, *et al.*: **Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk.** *Semin Vasc Med*. 2004; 4(3): 259–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Gaffney D, Reid JM, Cameron LM, *et al.*: **Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia.** *Arterioscler Thromb Vasc Biol*. 1995; 15(8): 1025–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Mahley RW, Innerarity TL, Rall SC Jr, *et al.*: **Plasma lipoproteins: apolipoprotein structure and function.** *J Lipid Res*. 1984; 25(12): 1277–1294.
[PubMed Abstract](#)
37. Mahley RW, Huang Y, Rall SC Jr: **Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes.** *J Lipid Res*. 1999; 40(11): 1933–1949.
[PubMed Abstract](#)
38. Kypreos KE, Li X, van Dijk KW, *et al.*: **Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.** *Biochemistry*. 2003; 42(33): 9841–9853.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Zannis VI, Breslow JL, Utermann G, *et al.*: **Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes.** *J Lipid Res*. 1982; 23(6): 911–914.
[PubMed Abstract](#)
40. Hixon JE, Vernier DT: **Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.** *J Lipid Res*. 1990; 31(3): 545–548.
[PubMed Abstract](#)
41. Arráiz N, Bermúdez V, Prieto C, *et al.*: **Association between apolipoprotein E gene polymorphism and hypercholesterolemic phenotype in Maracaibo, Zulia state, Venezuela.** *Am J Ther*. 2010; 17(3): 330–336.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Eichner JE, Dunn ST, Perveen G, *et al.*: **Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review.** *Am J Epidemiol*. 2002; 155(6): 487–495.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Schmidt K, Nouraeen A, Kronenberg F, *et al.*: **Structure, function, and genetics of lipoprotein (a).** *J Lipid Res*. 2016; 57(8): 1339–1359.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Bucci M, Tana C, Giamberardino MA, *et al.*: **Lp (a) and cardiovascular risk: Investigating the hidden side of the moon.** *Nutr Metab Cardiovasc Dis*. 2016; 26(11): 980–986.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Bermúdez V, Arraiz N, Cano C, *et al.*: **Lipoprotein (a): molecular and epidemiologic basis about its role in cardiovascular diseases.** *Revista Latinoamericana de Hipertensión*. 2008; 3(4): 113–122.
[Reference Source](#)
46. Bermúdez V, Arraiz N, Rojas E, *et al.*: **Abnormally high lipoprotein (a) levels in african-american communities from venezuela faced to other african-descending populations: are ethnic origins related?** *Revista Latinoamericana de Hipertensión*. 2008; 3(3): 66–72.
[Reference Source](#)
47. Parson W, Kraft HG, Niederstätter H, *et al.*: **A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein (a) results in a truncated protein and low plasma Lp (a).** *Hum Mutat*. 2004; 24(6): 474–480.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Verma P, Verma DK, Sethi R, *et al.*: **The rs2070895 (-250G/A) Single Nucleotide Polymorphism in Hepatic Lipase (HL) Gene and the Risk of Coronary Artery Disease in North Indian Population: A Case-Control Study.** *J Clin Diagn Res*. 2016; 10(8): GC01–06.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Eller P, Schgoer W, Mueller T, *et al.*: **Hepatic lipase polymorphism and increased risk of peripheral arterial disease.** *J Intern Med*. 2005; 258(4): 344–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Stroes E, Moulin P, Parhofer KG, *et al.*: **Diagnostic algorithm for familial chylomicronemia syndrome.** *Atheroscler Suppl*. 2017; 23(Supplement C): 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Clee SM, Loubser O, Collins J, *et al.*: **The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease.** *Clin Genet*. 2001; 60(4): 293–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Baggio G, Manzato E, Gabelli C, *et al.*: **Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.** *J Clin Invest*. 1986; 77(2): 520–527.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Oka K, Tkalecic GT, Nakano T, *et al.*: **Structure and polymorphic map of human lipoprotein lipase gene.** *Biochim Biophys Acta*. 1990; 1049(1): 21–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Deeb SS, Peng RL: **Structure of the human lipoprotein lipase gene.** *Biochemistry*. 1989; 28(10): 4131–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Eckel RH: **Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases.** *N Engl J Med*. 1989; 320(16): 1060–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Wang H, Eckel RH: **Lipoprotein lipase: from gene to obesity.** *Am J Physiol Endocrinol Metab*. 2009; 297(2): E271–288.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Fernández-Borja M, Bellido D, Vilella E, *et al.*: **Lipoprotein lipase-mediated uptake of lipoprotein in human fibroblasts: evidence for an LDL receptor-independent internalization pathway.** *J Lipid Res*. 1996; 37(3): 464–81.
[PubMed Abstract](#)
58. Daoud MS, Ataya FS, Fouad D, *et al.*: **Associations of three lipoprotein lipase**

- gene polymorphisms, lipid profiles and coronary artery disease. *Biomed Rep.* 2013; **1**(4): 573–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Gerdes C, Gerdes LU, Hansen PS, *et al.*: Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men. *Circulation.* 1995; **92**(7): 1765–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Heizmann C, Kirchgessner T, Kwiterovich PO, *et al.*: DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels. *Hum Genet.* 1991; **86**(6): 578–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Petrescu-Dănilă E, Voicu PM, Ionescu CR: [Mutagenic aspects of the lipoprotein lipase gene]. *Rev Med Chir Soc Med Nat Iasi.* 2006; **110**(1): 173–7.
[PubMed Abstract](#)
 62. Groenemijer BE, Hallman MD, Reymer PW, *et al.*: Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser⁴⁴⁷-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. *Circulation.* 1997; **95**(12): 2628–2635.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Cagatay P, Susleyici-Duman B, Ciftci C: Lipoprotein lipase gene PvuII polymorphism serum lipids and risk for coronary artery disease: meta-analysis. *Dis Markers.* 2007; **23**(3): 161–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Sayad A, Noruzinia M, Zamani M, *et al.*: Lipoprotein Lipase HindIII Intronic Polymorphism in a Subset of Iranian Patients with Late-Onset Alzheimer's Disease. *Cell J.* 2012; **14**(1): 67–72.
[PubMed Abstract](#) | [Free Full Text](#)
 65. Tanguturi PR, Pullareddy B, Krishna BR, *et al.*: Lipoprotein lipase gene HindIII polymorphism and risk of myocardial infarction in South Indian population. *Indian Heart J.* 2013; **65**(6): 653–657.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. Georges JL, Régis-Bailly A, Salah D, *et al.*: Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. *Genet Epidemiol.* 1996; **13**(2): 179–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Mattu RK, Needham EW, Morgan R, *et al.*: DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. *Arterioscler Thromb.* 1994; **14**(7): 1090–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Rios DL, Vargas AF, Ewald GM, *et al.*: Common variants in the lipoprotein lipase gene in Brazil: association with lipids and angiographically assessed coronary atherosclerosis. *Clin Chem Lab Med.* 2003; **41**(10): 1351–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Larson I, Hoffmann MM, Ordovas JM, *et al.*: The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL-cholesterol, but not with HDL and triglycerides in 342 females. *Clin Chem.* 1999; **45**(7): 963–8.
[PubMed Abstract](#)
 70. Razzaghi H, Aston CE, Hamman RF, *et al.*: Genetic screening of the lipoprotein lipase gene for mutations associated with high triglyceride/low HDL-cholesterol levels. *Hum Genet.* 2000; **107**(3): 257–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Holmer SR, Hengstenberg C, Mayer B, *et al.*: Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. *Cardiovasc Res.* 2000; **47**(4): 806–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Hemimi N, Salam ME, Abd-Elwahab M: The Lipoprotein Lipase HindIII Polymorphism And The Susceptibility To Hypertension. *Egypt J Biochem Mol Biol.* 2009; **27**(1).
[Publisher Full Text](#)
 73. Goodarzi MO, Guo X, Taylor KD, *et al.*: Lipoprotein lipase is a gene for insulin resistance in Mexican Americans. *Diabetes.* 2004; **53**(1): 214–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Mead JR, Cryer A, Ramji DP: Lipoprotein lipase, a key role in atherosclerosis? *FEBS Lett.* 1999; **462**(1–2): 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. *J Clin Endocrinol Metab.* 2001; **86**(2): 713–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Muñoz-Barrios S, Guzmán-Guzmán IP, Muñoz-Valle JF, *et al.*: Association of the HindIII and S447X polymorphisms in LPL gene with hypertension and type 2 diabetes in Mexican families. *Dis Markers.* 2012; **33**(6): 313–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Malygina NA, Melent'ev AS, Kostomarova IV, *et al.*: [Connection of HindIII-polymorphism in the lipoprotein lipase gene with myocardial infarct and life span in elderly ischemic heart disease patients]. *Mol Biol (Mosk).* 2001; **35**(5): 787–91.
[PubMed Abstract](#)
 78. Imeni M, Hasanzad M, Naji T, *et al.*: Analysis of the association Hind III Polymorphism of Lipoprotein Lipase gene on the risk of coronary artery disease. *Res Mol Med.* 2013; **1**(3): 19–24.
[Publisher Full Text](#)
 79. Shimo-Nakanishi Y, Urabe T, Hattori N, *et al.*: Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. *Stroke.* 2001; **32**(7): 1481–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. He T, Wang J, Deng WS, *et al.*: Association between Lipoprotein Lipase Polymorphism and the Risk of Stroke: A Meta-analysis. *J Stroke Cerebrovasc Dis.* 2017; **26**(11): 2570–2578.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 01 October 2018

<https://doi.org/10.5256/f1000research.17787.r38893>

© 2018 Aguilar-Salinas C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Carlos Aguilar-Salinas

Instituto Nacional de Ciencias Médicas y Nutrición, Unidad de Investigación de Enfermedades Metabólicas, México City, Mexico

No additional comments.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 05 March 2018

<https://doi.org/10.5256/f1000research.14029.r31173>

© 2018 Aguilar-Salinas C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Carlos Aguilar-Salinas

Instituto Nacional de Ciencias Médicas y Nutrición, Unidad de Investigación de Enfermedades Metabólicas, México City, Mexico

Authors of the paper "Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism" summarizes several papers published by Latin American researchers about lipid disorders. The document highlight the need for more studies about genetics of dyslipidemia in this region.

The main limitations of the study are:

- The paper covers a large number of topics. As a result, information is presented without a critical analyses. Since the HindIII polymorphism is the main issue under review, a large proportion of the review could be summarized and the HindIII polymorphism data extended. For example, the genes involved in familial hypoalphalipoproteinemia are enlisted partially (i.e. ABCA1 was not mentioned). It is not clear the reason to devote several paragraphs for FH genes when they are not related with the main topic of this review.
- Reasons for the large differences in the prevalence of the lipid disorders between Latin-American surveys could be critically discussed.
- The style of the manuscript could be upgraded. The flow of the information should be improved.
- It is kindly suggested to consider a redesign of the structure of the document.

Is the topic of the review discussed comprehensively in the context of the current literature?

Partly

Are all factual statements correct and adequately supported by citations?

Partly

Is the review written in accessible language?

Partly

Are the conclusions drawn appropriate in the context of the current research literature?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 19 January 2018

<https://doi.org/10.5256/f1000research.14029.r30011>

© 2018 Galton D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David J. Galton

Wolfson Institute of Preventive Medicine, The Royal London and St. Bartholomew's Hospitals,

London, UK

This review deals with the following genes involved in lipid metabolism: CETP, LCAT, LDL receptor, apoE, Lp(a), hepatic lipase and lipoprotein lipase. However it misses out details of the apoC3 gene which is the only one in which a specific therapy (volanesorsen) has been developed. A review of this can be found in Galton (2017)¹.

The authors then go on to deal with the Hind 111 polymorphism of Lipoprotein lipase. A common *HindIII* polymorphism in intron 8 (T/G) of the LPL gene has been found to be associated with altered plasma TG and HDL-cholesterol, and CAD risk in several studies, but they do not comment on its functional significance.

It is known that certain intronic sequence contain regulatory elements that are important for transcription and translational regulation of a gene. A recent study (Chen et al. (2008)²) showed that this Hind 111 polymorphism affects the binding site of a transcription factor that regulates the transcription of LPL gene. Electrophoretic mobility shift assays revealed that the *HindIII* site binds to a transcription factor and that the mutant allele has lower binding affinity than the wild type allele. Transcription assays containing the entire intron 8 sequence along with full-length human LPL promoter were carried out in COS-1 and human vascular smooth muscle cells. The mutant allele was associated with significantly decreased luciferase expression level compared to the wild type allele in both the muscle (3.394 ± 0.022 vs. 4.184 ± 0.028 ; $P=4.7 \times 10^{-6}$) and COS-1 (11.603 ± 0.409 vs. 14.373 ± 1.096 ; $P<0.0001$) cells. This study demonstrates for the first time that the polymorphic *HindIII* site in the LPL gene is functional because it affects the binding of a transcription factor and it also has an impact on LPL expression.

References

1. Galton DJ: Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis. *Curr Opin Lipidol.* 2017; **28** (4): 308-312 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Chen Q, Razzaghi H, Demirci FY, Kambouh MI: Functional significance of lipoprotein lipase *HindIII* polymorphism associated with the risk of coronary artery disease. *Atherosclerosis.* 2008; **200** (1): 102-8 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the topic of the review discussed comprehensively in the context of the current literature?

Partly

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research